{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma%2C+Grade+3&page=2", "query": { "condition": "Follicular Lymphoma, Grade 3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma%2C+Grade+3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T04:28:26.933Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00474929", "title": "Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 103, "start_date": "2007-08-29", "completion_date": "2019-08-08", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474929" }, { "nct_id": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2005-12-13", "completion_date": "2018-03-11", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Basking Ridge, New Jersey • New Brunswick, New Jersey + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295932" }, { "nct_id": "NCT00003406", "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cancer Treatment Centers of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 30, "start_date": "1997-10", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-03-26", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 1, "location_summary": "Zion, Illinois", "locations": [ { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003406" }, { "nct_id": "NCT00238238", "title": "Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2006-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 79, "location_summary": "La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 48 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238238" }, { "nct_id": "NCT06666712", "title": "Chronic CED of TPT for Recurrent Malignant Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent", "Malignant Glioma (WHO Grade III or IV)", "IDH1/IDH2 Mutation" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey N. Bruce", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2026-06-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06666712" }, { "nct_id": "NCT01144247", "title": "Cellular Immunotherapy Study for Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliomas", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Mixed Glioma", "Glioblastoma Multiforme", "Malignant Meningioma" ], "interventions": [ { "name": "alloreactive CTL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2010-07", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-05-27", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01144247" }, { "nct_id": "NCT00293488", "title": "SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "polyamine analogue PG11047", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Progen Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-06-23", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00293488" }, { "nct_id": "NCT00006079", "title": "Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Precancerous Condition" ], "interventions": [ { "name": "Eflornithine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "1998-06-19", "completion_date": "2004-04-27", "has_results": false, "last_update_posted_date": "2018-10-25", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006079" }, { "nct_id": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Chronic Lymphocytic Leukemia", "Cutaneous B-Cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "HIV Infection", "Intraocular Lymphoma", "Multicentric Angiofollicular Lymphoid Hyperplasia", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Plasma Cell Myeloma", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2014-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 7, "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109224" }, { "nct_id": "NCT00006669", "title": "Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "EPOCH regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "1999-09", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-07-24T04:28:26.933Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006669" } ] }